Table 104-1 Acute Myeloid Leukemia (AML) Classification Systems World Health Organization Classificationa I. AML with recurrent genetic abnormalities AML with t(8;21)(q22;q22);RUNX1/RUNX1T1b AML with abnormal bone marrow eosinophils [inv(16)(p13q22) or t(16;16)(p13;q22);CBFB/MYH11]b Acute promyelocytic leukemia [AML with t(15;17)(q22;q12) (PML/RARα) and variants]b AML with 11q23 (MLL) abnormalities II. AML with multilineage dysplasia Following a myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative disorder Without antecedent myelodysplastic syndrome III. AML and myelodysplastic syndromes, therapy-related Alkylating agent–related Topoisomerase type II inhibitor–related Other types IV. AML not otherwise categorized AML minimally differentiated AML without maturation AML with maturation Acute myelomonocytic leukemia Acute monoblastic and monocytic leukemia . | Chapter 104. Acute and Chronic Myeloid Leukemia Part 2 Table 104-1 Acute Myeloid Leukemia AML Classification Systems World Health Organization Classification I. AML with recurrent genetic abnormalities AML with t 8 21 q22 q22 RUNX1 RUNX1T1b AML with abnormal bone marrow eosinophils inv 16 p13q22 or t 16 16 p13 q22 CBFB MYH11 b Acute promyelocytic leukemia AML with t 15 17 q22 q12 PML RARa and variants b AML with 11q23 MLL abnormalities II. AML with multilineage dysplasia Following a myelodysplastic syndrome or myelodysplastic syndrome myeloproliferative disorder Without antecedent myelodysplastic syndrome III. AML and myelodysplastic syndromes therapy-related Alkylating agent-related Topoisomerase type II inhibitor-related Other types IV. AML not otherwise categorized AML minimally differentiated AML without maturation AML with maturation Acute myelomonocytic leukemia Acute monoblastic and monocytic leukemia Acute erythroid leukemia Acute megakaryoblastic leukemia Acute basophilic leukemia Acute panmyelosis with myelofibrosis Myeloid sarcoma French-American-British FAB Classificationc Incidence M0 Minimally differentiated leukemia 5 M1 Myeloblastic leukemia without maturation 20 M2 Myeloblastic leukemia with maturation 30 M3 Hypergranular promyelocytic leukemia 10
